
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
---|---|---|---|---|---|---|
05/07/2025 | Q1 | -- | $179.6M | $0.86 | -- | -- |
03/10/2025 | Q4 | -- | $136.2M | -$0.81 | -- | -- |
11/04/2024 | Q3 | -- | $168.2M | $1.01 | -- | -- |
08/06/2024 | Q2 | -- | $170.5M | $0.23 | -- | -- |
05/08/2024 | Q1 | -- | $173.1M | $0.78 | -- | -- |
03/05/2024 | Q4 | -- | $154.6M | $0.51 | -- | -- |
11/08/2023 | Q3 | -- | -- | $0.39 | -- | -- |
08/02/2023 | Q2 | -- | -- | $1.32 | -- | -- |
05/09/2023 | Q1 | -- | -- | $0.17 | -- | -- |
03/08/2023 | Q4 | -- | -- | $0.91 | -- | -- |
11/02/2022 | Q3 | -- | -- | -$0.56 | -- | -- |
08/02/2022 | Q2 | -- | -- | $0.37 | -- | -- |
05/03/2022 | Q1 | -- | -- | -$0.17 | -- | -- |
03/08/2022 | Q4 | -- | -- | $0.71 | -- | -- |
11/03/2021 | Q3 | -- | -- | -$0.42 | -- | -- |
08/03/2021 | Q2 | -- | -- | $0.02 | -- | -- |
05/05/2021 | Q1 | -- | -- | $0.19 | -- | -- |
03/10/2021 | Q4 | -- | -- | $1.20 | -- | -- |
11/04/2020 | Q3 | -- | -- | $0.06 | -- | -- |
08/05/2020 | Q2 | -- | -- | -$0.00 | -- | -- |
05/05/2020 | Q1 | -- | -- | -$1.11 | -- | -- |
12/31/2019 | Q4 | -- | -- | -$0.83 | -- | -- |
09/30/2019 | Q3 | -- | -- | $0.14 | -- | -- |
02/27/2019 | Q4 | -- | -- | -$2.39 | -$2.23 | -$0.16 |
11/05/2018 | Q3 | -- | -- | -$2.48 | -$2.54 | $0.06 |
07/31/2018 | Q2 | -- | -- | -$1.01 | -$1.01 | -$0.00 |
04/30/2018 | Q1 | -- | -- | -$3.85 | -$4.44 | $0.59 |
02/20/2018 | Q4 | -- | -- | -$1.02 | -$0.54 | -$0.48 |
10/30/2017 | Q3 | -- | -- | $0.53 | $0.61 | -$0.08 |
07/31/2017 | Q2 | -- | -- | -$0.96 | -$1.10 | $0.14 |
05/02/2017 | Q1 | -- | -- | $0.22 | $0.28 | -$0.06 |
02/22/2017 | Q4 | -- | -- | $1.31 | $1.39 | -$0.08 |
11/08/2016 | Q3 | -- | -- | $0.80 | $1.15 | -$0.35 |
08/02/2016 | Q2 | -- | -- | -- | -- | -- |
05/03/2016 | Q1 | -- | -- | $0.77 | -- | -- |
02/22/2016 | Q4 | -- | -- | -- | -- | -- |
10/29/2015 | Q3 | -- | -- | -- | -- | -- |
Greenlight Capital Re reported $179.6M worth of top line sales in its most recent quarter.
Greenlight Capital Re announced earnings per share of $0.86 which represents a beat of analyst forecast a -- per share.
Greenlight Capital Re reported -- that represents -- per share over the last quarter.
Greenlight Capital Re's earnings are forecast to grow from $1.24 per share to -- per share next year representing an increase of --.
Greenlight Capital Re's next earnings date is August 6, 2025.
Signup to receive the latest stock alerts
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Market Cap: $4.2T
P/E Ratio: 58x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 35x
SharpLink Gaming [SBET] is down 2.6% over the past day.
Exodus Movement [EXOD] is down 4.14% over the past day.
Unity Software [U] is up 7.51% over the past day.